Headlands Technologies LLC Bei Gene, Ltd. Transaction History
Headlands Technologies LLC
- $401 Million
- Q1 2024
A detailed history of Headlands Technologies LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Headlands Technologies LLC holds 322 shares of BGNE stock, worth $47,024. This represents 0.01% of its overall portfolio holdings.
Number of Shares
322Holding current value
$47,024% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
215Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.54 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.03 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$756 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$730 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$545 Million0.46% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $15.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...